Skip to main content
Top
Published in: Journal of Gastrointestinal Cancer 4/2010

01-12-2010 | Original Research

The Surgical Treatment and Outcome for Primary Duodenal Adenocarcinoma

Authors: Shao-Liang Han, Jun Cheng, Hong-Zhong Zhou, Qi-Qiang Zeng, Sheng-Hong Lan

Published in: Journal of Gastrointestinal Cancer | Issue 4/2010

Login to get access

Abstract

Background

To investigate the early diagnosis and outcomes of surgical treatment of primary duodenal adenocarcinoma (PDAC) for curative purpose.

Method

Thirty-two PDAC patients treated surgically between February 1990 and September 2006 were analyzed retrospectively.

Results

All 32 patients underwent laparotomy including 18 (56.3%) pancreaticoduodenectomy (PD), six (18.7%) segmental resection (SR), and eight bypass procedures. And R0 resections were obtained in 22 patients; the other ten procedures were palliative. The total 1-, 3-, and 5-year survival rates in this study were 78.1% (25/32), 43.8% (14/32), and 18.8% (6/32), respectively; moreover, the 1-, 3-, and 5-year survival rates in patients with R0 resection were 100.0% (20/20), 70.0% (14/20), and 30.0% (6/20), which were significantly higher than those (41.7% = 5/12, 0%, and 0%) in patients with palliative operation (P < 0.05), respectively. Furthermore, the 5-year survival rate was 27.8% (5/18) in pancreaticoduodenectomy patients and 16.7% (1/6) in segmental resection patients, and there was no significant difference between the above two procedures (P > 0.05).

Conclusion

PD is suggested for tumor located at the first and second portion of the duodenum, and SR may be appropriate for the selected patients especially for tumors of the distal duodenum.
Literature
1.
2.
go back to reference Egberts JH, Scharrer ML, Hinz S, Schafmayer C, Klomp HJ, Faendrich F, et al. Small bowel cancer: single-centre results over a period of 12 years. Hepatogastroenterology. 2007;54(73):129–34.PubMed Egberts JH, Scharrer ML, Hinz S, Schafmayer C, Klomp HJ, Faendrich F, et al. Small bowel cancer: single-centre results over a period of 12 years. Hepatogastroenterology. 2007;54(73):129–34.PubMed
3.
go back to reference Hu JX, Miao XY, Zhong DW, Dai WD, Liu W, Hu W. Surgical treatment of primary duodenal adenocarcinoma. Hepatogastroenterology. 2006;53(72):858–62.PubMed Hu JX, Miao XY, Zhong DW, Dai WD, Liu W, Hu W. Surgical treatment of primary duodenal adenocarcinoma. Hepatogastroenterology. 2006;53(72):858–62.PubMed
4.
go back to reference Shao YF, Wu TC, Shan Y, Wu JX, Wang X, Zhao P. Clinico-pathological characteristics of surgical effect on periampullary cancers: report of 631 cases. Zhonghua Yi Xue Za Zhi. 2005;85(8):510–13.PubMed Shao YF, Wu TC, Shan Y, Wu JX, Wang X, Zhao P. Clinico-pathological characteristics of surgical effect on periampullary cancers: report of 631 cases. Zhonghua Yi Xue Za Zhi. 2005;85(8):510–13.PubMed
5.
go back to reference Ramia JM, Villar J, Palomeque A, Muffak K, Mansilla A, Garrote D, et al. Duodenal adenocarcinoma. Cir Esp. 2005;77(4):208–12.PubMedCrossRef Ramia JM, Villar J, Palomeque A, Muffak K, Mansilla A, Garrote D, et al. Duodenal adenocarcinoma. Cir Esp. 2005;77(4):208–12.PubMedCrossRef
6.
go back to reference Saiura A, Yamamoto J, Yamaguchi T. Primary duodenal carcinoma. Gan To Kagaku Ryoho. 2004;31(3):327–30.PubMed Saiura A, Yamamoto J, Yamaguchi T. Primary duodenal carcinoma. Gan To Kagaku Ryoho. 2004;31(3):327–30.PubMed
7.
go back to reference Liu JF, Li A, Liu Q, Zhou JS, Sun JB, Li D. Surgical treatment of 475 patients with periampullary carcinoma. Zhonghua Zhong Zhong Liu Za Zhi. 2005;27(4):251–3. Liu JF, Li A, Liu Q, Zhou JS, Sun JB, Li D. Surgical treatment of 475 patients with periampullary carcinoma. Zhonghua Zhong Zhong Liu Za Zhi. 2005;27(4):251–3.
8.
go back to reference Kaklamanos IG, Bathe OF, Franceschi D, Camarda C, Levi J, Livingstone AS. Extent of resection in the management of duodenal adenocarcinoma. Am J Surg. 2000;179(1):37–41.PubMedCrossRef Kaklamanos IG, Bathe OF, Franceschi D, Camarda C, Levi J, Livingstone AS. Extent of resection in the management of duodenal adenocarcinoma. Am J Surg. 2000;179(1):37–41.PubMedCrossRef
9.
go back to reference Lowell JA, Rossi RL, Munson JL, Braasch JW. Primary adenocarcinoma of third and fourth portions of duodenum. Favorable prognosis after resection. Arch Surg. 1992;127(5):557–60.PubMedCrossRef Lowell JA, Rossi RL, Munson JL, Braasch JW. Primary adenocarcinoma of third and fourth portions of duodenum. Favorable prognosis after resection. Arch Surg. 1992;127(5):557–60.PubMedCrossRef
10.
go back to reference Small Intestine. In: American joint committee on cancer: manual for staging of cancer. Beahrs OH, Hason DE, Hutter RVP, Kennedy BJ, Editor. Philadelphia: JB Lippincott Co, 1992. p 69–73. Small Intestine. In: American joint committee on cancer: manual for staging of cancer. Beahrs OH, Hason DE, Hutter RVP, Kennedy BJ, Editor. Philadelphia: JB Lippincott Co, 1992. p 69–73.
11.
go back to reference Declore R, Thomas JH, Forster J. Improving resectability and survival in patients with primary duodenal carcinoma. Am J Surg. 1993;166(12):626–31. Declore R, Thomas JH, Forster J. Improving resectability and survival in patients with primary duodenal carcinoma. Am J Surg. 1993;166(12):626–31.
12.
go back to reference Lang H, Nadalin S, Raab R, Jahne J. Results of surgical therapy of primary adenocarcinoma of the duodenum. Chirurg. 1999;70(5):571–7.PubMedCrossRef Lang H, Nadalin S, Raab R, Jahne J. Results of surgical therapy of primary adenocarcinoma of the duodenum. Chirurg. 1999;70(5):571–7.PubMedCrossRef
13.
go back to reference Kazerooni EA, Quint LE, Francis IR. Duodenal neoplasm: predictive value of CT for determining malignancy and tumor resectability. AJR Am J Roentgenol. 1992;159(2):303–9.PubMed Kazerooni EA, Quint LE, Francis IR. Duodenal neoplasm: predictive value of CT for determining malignancy and tumor resectability. AJR Am J Roentgenol. 1992;159(2):303–9.PubMed
14.
go back to reference Jurisic D, Doko M, Glavan E, Rosko D, Vidovic D, Tomic K. Local recurrence of primary non-ampullary adenocarcinoma of duodenum after surgical treatment—a case report and a literature review. Coll Antropo. 2006;30(1):225–9. Jurisic D, Doko M, Glavan E, Rosko D, Vidovic D, Tomic K. Local recurrence of primary non-ampullary adenocarcinoma of duodenum after surgical treatment—a case report and a literature review. Coll Antropo. 2006;30(1):225–9.
15.
go back to reference Santoro E, Sacchi M, Scutari F, Carboni F, Graziano F. Primary adenocarcinoma of the duodenum: treatment and survival in 89 patients. Hepatogastroenterology. 1997;44(16):1157–63.PubMed Santoro E, Sacchi M, Scutari F, Carboni F, Graziano F. Primary adenocarcinoma of the duodenum: treatment and survival in 89 patients. Hepatogastroenterology. 1997;44(16):1157–63.PubMed
16.
go back to reference Bucher P, Gervaz P, Morel P. Long-term results of radical resection for locally advanced duodenal adenocarcinoma. Hepatogastroenterology. 2005;52(66):1727–9.PubMed Bucher P, Gervaz P, Morel P. Long-term results of radical resection for locally advanced duodenal adenocarcinoma. Hepatogastroenterology. 2005;52(66):1727–9.PubMed
17.
go back to reference Stell D, Mayer D, Mirza D, Buckels J. Delayed diagnosis and lower resection rate of adenocarcinoma of the distal duodenum. Dig Surg. 2004;21(5–6):434–8.PubMedCrossRef Stell D, Mayer D, Mirza D, Buckels J. Delayed diagnosis and lower resection rate of adenocarcinoma of the distal duodenum. Dig Surg. 2004;21(5–6):434–8.PubMedCrossRef
18.
go back to reference Bakaeen FG, Murr MM, Sarr MG, Thompson GB, Farnell MB, Nagorney DM, et al. What prognostic factors are important in duodenal adenocarcinoma? Arch Surg. 2000;135(6):635–41.PubMedCrossRef Bakaeen FG, Murr MM, Sarr MG, Thompson GB, Farnell MB, Nagorney DM, et al. What prognostic factors are important in duodenal adenocarcinoma? Arch Surg. 2000;135(6):635–41.PubMedCrossRef
19.
go back to reference Bal A, Joshi K, Vaiphei K, Wig JD. Primary duodenal neoplasms: a retrospective clinicopathological analysis. World J Gastroenterol. 2007;13(7):1108–11.PubMed Bal A, Joshi K, Vaiphei K, Wig JD. Primary duodenal neoplasms: a retrospective clinicopathological analysis. World J Gastroenterol. 2007;13(7):1108–11.PubMed
20.
go back to reference Yang YM, Tian XD, Zhuang Y, Wang WH, Wan YL, Huang YT. Risk factors of pancreatic leakage after pancreaticoduodenectomy. World J Gastroenterol. 2005;11(16):2456–61.PubMed Yang YM, Tian XD, Zhuang Y, Wang WH, Wan YL, Huang YT. Risk factors of pancreatic leakage after pancreaticoduodenectomy. World J Gastroenterol. 2005;11(16):2456–61.PubMed
21.
go back to reference Gibson MK, Holcroft CA, Kvols LK, Haller D. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. Oncologist. 2005;10(2):132–7.PubMedCrossRef Gibson MK, Holcroft CA, Kvols LK, Haller D. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. Oncologist. 2005;10(2):132–7.PubMedCrossRef
Metadata
Title
The Surgical Treatment and Outcome for Primary Duodenal Adenocarcinoma
Authors
Shao-Liang Han
Jun Cheng
Hong-Zhong Zhou
Qi-Qiang Zeng
Sheng-Hong Lan
Publication date
01-12-2010
Publisher
Springer US
Published in
Journal of Gastrointestinal Cancer / Issue 4/2010
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-010-9160-1

Other articles of this Issue 4/2010

Journal of Gastrointestinal Cancer 4/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.